Kling Bio, a biotech company developing antibody-based drugs against targets identified from its immortalised B-cell platform, is pleased to announce the appointment of Dr Stefano Gullà as Chief Scientific Officer.
Dr Gullà is a seasoned industry veteran with more than 15 years of experience in biotherapeutics discovery and development.
Prior to joining Kling, Dr Gullà held senior positions at Pfizer, Agenus, Flagship and RVAC where he led the discovery and development of its first-in-class therapeutics with applications in immuno-oncology and autoimmunity.
Commenting on the appointment, Michael Koslowski, Chief Executive Officer of Kling Bio, said: “Kling will benefit immensely from Stefano’s proven leadership skills and in-depth scientific knowledge."
"I am confident Stefano will help guide and execute our vision for Kling during this pivotal phase of company growth, as we accelerate to become a world-leading drug discovery and development company.”
Stefano Gullà commented: “Kling’s technology is a powerful discovery engine that enables simultaneous and unbiased identification of new targets and therapeutic antibodies."
"I am excited about the potential to scale this clinically proven platform, focusing on cancer and emerging infectious diseases, and look forward to working with Kling’s exceptionally talented leadership team to continue building value for patients by advancing life changing medicines into the clinic.”
